We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Rhenovia Signs Two-year EUR 500,000 Partnership with AFM for Diseases of the Nervous System

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Rhenovia Signs Two-year EUR 500,000 Partnership with AFM for Diseases of the Nervous System"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Rhenovia Pharma SAS, announces that it has signed a strategic partnership agreement with the French Muscular Dystrophy Association (Association Française contre les Myopathies – AFM). The two-year agreement is worth more than 500,000 Euros.

This strategic collaboration is aimed at speeding up the development of Rhenovia’s technology for simulating neuronal transmission and pushing ahead with experimental validation so as to be able to apply the technology faster. It will give AFM access to a speedier scientific approach for discovering and developing new pharmacological treatments for rare neurodegenerative diseases. This approach will also benefit pathologies that affect larger patient numbers, such as Alzheimer’s and Parkinson’s.

Rhenovia’s neuronal transmission biosimulation platform is currently the most sophisticated simulation technology used in research into new medicines for diseases affecting the brain. It also improves the efficacy and/or the side-effect profiles of existing medicines and enables drug candidates sidelined by the pharmaceutical industry to be reassessed.

The Rhenovia platform is capable of reproducing experimental results on a computer and, conversely, of predicting the effects of medicines whose efficacy can then be confirmed experimentally. This technology brings a reduction in costs, since part of the research on animal models is replaced by computer studies, improves the success rate for drug candidates by taking account of physiological and pathological realities, and reduces the time to market (fewer false leads, etc.).